A 52-year-old man with a 10-year history of chronic pancreatitis presents with steatorrhea, weight loss of 8 kg over 3 months, and fat-soluble vitamin deficiencies. Fecal chymotrypsin is absent. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context This patient has **pancreatic insufficiency** (evidenced by absent fecal chymotrypsin and steatorrhea) secondary to chronic pancreatitis. The deficiency of pancreatic enzymes — lipase, amylase, and proteases — leads to malabsorption of fats and fat-soluble vitamins (A, D, E, K). ## Pathophysiology of Pancreatic Enzyme Secretion **Key Point:** The pancreas secretes ~1500 mL of enzyme-rich juice daily. In chronic pancreatitis, progressive fibrosis and acinar cell loss reduce enzyme output below the threshold needed for normal digestion (~10% of normal capacity is sufficient for adequate fat digestion). ## Management Algorithm for Pancreatic Insufficiency ```mermaid flowchart TD A[Chronic pancreatitis + steatorrhea]:::outcome --> B{Fecal chymotrypsin?}:::decision B -->|Absent| C[Pancreatic insufficiency confirmed]:::outcome C --> D[Pancreatic enzyme replacement]:::action D --> E[Assess response in 2-4 weeks]:::decision E -->|Improved| F[Continue therapy + fat-soluble vitamin supplements]:::action E -->|No improvement| G[Increase enzyme dose or add H2 blocker/PPI]:::action G --> H{Persistent symptoms?}:::decision H -->|Yes| I[Consider ERCP if ductal obstruction suspected]:::action H -->|No| J[Maintenance therapy]:::outcome ``` ## Why Pancreatic Enzyme Replacement Is First-Line | Feature | Pancreatic Enzyme Replacement | ERCP | Octreotide | Surgery | |---------|------------------------------|------|-----------|----------| | **Indication** | All pancreatic insufficiency | Ductal obstruction, pain | Refractory pain, secretory diarrhea | Intractable pain, failed conservative Rx | | **Timing** | Immediate, first-line | After imaging confirmation | Adjunctive | Last resort | | **Mechanism** | Replaces deficient enzymes | Relieves ductal obstruction | Suppresses secretion | Removes diseased tissue | | **Evidence** | Level 1 (multiple RCTs) | Level 2 (observational) | Level 2 | Level 2 | **High-Yield:** Pancreatic enzyme supplements must be taken **with meals** and in **adequate doses** (typically 25,000–40,000 units of lipase per meal). Enteric-coated formulations protect enzymes from gastric acid inactivation. ## Adjunctive Measures **Key Point:** Concurrent treatment includes: - Fat-soluble vitamin supplementation (A, D, E, K) — malabsorption is inevitable - Proton pump inhibitors (PPIs) — reduce gastric acid, which inactivates exogenous enzymes - Dietary fat restriction (if severe steatorrhea persists) **Clinical Pearl:** The presence of steatorrhea (>7 g fat/24 h stool) with absent fecal chymotrypsin is pathognomonic for pancreatic insufficiency, not biliary disease. This patient needs enzyme replacement, not ERCP. ## Why Other Options Are Incorrect at This Stage - **ERCP** is reserved for ductal obstruction (strictures, stones) causing pain or cholestasis — not the primary treatment for enzyme deficiency. - **Octreotide** suppresses pancreatic secretion but does NOT replace missing enzymes; it is used for pain control in chronic pancreatitis, not malabsorption. - **Surgery** is a last resort for intractable pain or complications, not for uncomplicated pancreatic insufficiency.